NDAORALSUSPENSION
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
5/8 — Partial
ATMEKSI (methocarbamol) by Baxter is 12. Approved for pain. First approved in 2025.
Drug data last refreshed 19h ago
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of methocarbamol in humans has not been established but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber. 12.3…
Worked on ATMEKSI at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.